Skip to content

Role of Jivantyadi churna in the management of Tamaka Shwasa

Management of Tamaka Shwasa (Bronchial Asthma) in Children with Jivantyadi Churna and Shwasahara Dashemani Churna - An Open Labelled, Randomized, Comparative Clinical Trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/12/010793
Enrollment
30
Registered
2017-12-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients having sign and symptoms of bronchial asthma

Interventions

Intervention1: in Group A Jivantyadi Churna referance Astang Hridya Chikitsa sthana Shlok no 4/43-45: 18 drugs of Jivantyadi churna named as Jivanti Leptadenia reticulata W & R Nagarmotha Cyperus rota

Sponsors

Director IPGT and RA GAU JAMNAGAR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients of 2 â?? 12 years of age group of either sex 2 Diagnosed cases of Tamaka Shwasa (Bronchial Asthma) with at least 2 episodes of asthma symptoms during the previous year 3 Patients on other drug therapy will be included only after completion of wash out period of 2 weeks 4 Mild persistent asthmatic patients 5 Patients on other drug therapy will be included only after completion

Exclusion criteria

Exclusion criteria: 1 Children of age below 2 years and above 12 years 2 Patients with status asthmatics Evidence of active Concomitant Pulmonary Diseases other than asthma 3 Evidence of requirement of intubations for asthma or had been hospitalized for asthma within one month before Unresolved Sinus Disease or an unresolved upper or lower respiratory tract infection within 4 weeks 4 Concomitant severe de-compensated systemic disease (cardiovascular renal hepatic endocrine hematological neurological immunological).

Design outcomes

Primary

MeasureTime frame
relieve in the sign and symptom of shwasa roga or Bronchial asthmaTimepoint: 8 weeks

Secondary

MeasureTime frame
To prevent the recurrence of attack of breathlessness To increase the immunity against allergensTimepoint: 8 weeks

Countries

India

Contacts

Public ContactDr V K Kori

IPGT AND RA JAMNAGAR

drkspatel2007@yahoo.co.in9427574566

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026